![Juniper Biologics signs exclusive license agreement with Helsinn Healthcare SA for LEDAGA® (chlormethine) in Australia, Asia and the Middle East Juniper Biologics signs exclusive license agreement with Helsinn Healthcare SA for LEDAGA® (chlormethine) in Australia, Asia and the Middle East](https://www.biopharmaapac.com/uploads/articles/oip_2-1948.jpg)
Juniper Biologics signs exclusive license agreement with Helsinn Healthcare SA for LEDAGA® (chlormethine) in Australia, Asia and the Middle East
![The optimal use of chlormethine gel for mycosis fungoides: An expert consensus from Germany, Austria and Switzerland (DACH region) - Assaf - 2022 - JDDG: Journal der Deutschen Dermatologischen Gesellschaft - Wiley Online Library The optimal use of chlormethine gel for mycosis fungoides: An expert consensus from Germany, Austria and Switzerland (DACH region) - Assaf - 2022 - JDDG: Journal der Deutschen Dermatologischen Gesellschaft - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/0256491d-c172-48bf-a3d1-76c33a3e1e43/ddg.v20.5.cover.jpg?trick=1702278279277)
The optimal use of chlormethine gel for mycosis fungoides: An expert consensus from Germany, Austria and Switzerland (DACH region) - Assaf - 2022 - JDDG: Journal der Deutschen Dermatologischen Gesellschaft - Wiley Online Library
1 Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety Lugano, Switzerlan
![The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma | springermedizin.de The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma | springermedizin.de](https://media.springernature.com/lw150/springer-static/cover/journal/40257/22/3.jpg?as=jpg)